<DOC>
	<DOCNO>NCT02569801</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy , safety , tolerability GDC-0810 compare fulvestrant postmenopausal woman advance metastatic estrogen receptor positive ( ER+ ) / human epidermal growth factor receptor 2 negative ( HER2 ) breast cancer resistant aromatase inhibitor therapy .</brief_summary>
	<brief_title>A Study GDC-0810 Versus Fulvestrant Women With Advanced Metastatic Breast Cancer Resistant Aromatase Inhibitor Therapy ( HydranGea )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal woman histologically cytologically confirm metastatic inoperable , locally advance breast cancer Participants endocrine therapy recommend treatment cytotoxic chemotherapy indicate time entry study Participants must measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 nonmeasurable , evaluable disease atleast one evaluable bone lesion RECIST v1.1 Participants must radiologic/objective evidence breast cancer recurrence progression within 6 month end adjuvant treatment Aromatase Inhibitor ( AI ) , progression within 1 month end prior AI treatment locally advance Metastatic Breast Cancer Participants must Estrogen Receptor Positive ( ER+ ) disease HER2 positive disease Prior treatment fulvestrant Prior treatment great ( &gt; ) 1 cytotoxic chemotherapy regimen Prior treatment &gt; 2 endocrine therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>